All News

Laura Steele will lead Lilly’s commercial business operations in six countries, across the company’s current and emerging portfolio in Diabetes, Oncology, Immunology and Neuroscience.

What can both public and private sector stakeholders learn from current trends to accelerate innovation around the COVID-19 pandemic and other emerging global health threats, including antimicrobial resistance?

New findings detail how executives handle compliance challenges.

Will oversee global acceleration and scaling of ZS’ portfolio of life sciences and healthcare work.

Novartis and the Novartis US Foundation have launched a 10-year commitment to co-create programs “that address the root causes of systemic disparities in health outcomes and create greater diversity, equity and inclusion across the research and development ecosystem.”

ProductLife Group has announced its acquisition of Czech Republic-based global regulatory outsourcing company, ELC Group.

Brand refresh aligns with company‘s purpose to enable healthcare organizations to be “future ready.”

Healthcare Businesswomen’s Association appointment ushers in a new chapter in its mission of advancing women in healthcare.

Acquisition is largest in 37-year history of ZS.

California-based healthcare communications firm will be fully integrated into Fingerpaint.

New solution addresses pricing pressures and streamlines order-to-cash process.

What are the reasons behind the slump and what does the future hold?

The recent FDA approval of Biogen’s controversial drug aducanumab is the first drug approved for Alzheimer’s disease in nearly 20 years, and highlights the urgent need for new disease modifying approaches in drug development in this indication.

Janssen has launched series of videos and written perspectives on The Mighty, an online patient network, to highlight the stories of individuals living with pulmonary arterial hypertension (PAH).

It's time to apply the same COVID-19 urgency to other devastating diseases, such as Alzheimer’s, write Andrea Pfeifer and William Mobley.

NURTEC ODT approved for the preventive treatment of adult patients who experience less than 15 headache days per month.

The European Commission’s Genetically Modified Organism (GMO) legislation hurts Europe’s ability to attract clinical trials and delays patient access to transformative medicines, say European industry associations.

Becton, Dickinson and Company is to build a $200 million high-tech manufacturing facility in Zaragoza, Spain.

Deloitte acquires Iperion Life Sciences, which will now run as part of Deloitte’s Risk Advisory function.

Forecast excludes spending on COVID-19 vaccines, according to IQVIA Institute for Human Data Science study.

Specialized Intensive Learning Academies (ILAs) "will deliver transformational training and support across preventative health, value-based health and care, and innovations in health and social care."

Multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE platform to discover controllable genetic therapies to treat serious diseases.

Ethics and diversity on full display across pharma industry.

A picture of wide manufacturing violations appears in a recently disclosed FDA form 483 report on a site visit to Emergent’s Baltimore vaccine plant.

Next tier of markets is poised to ascend and offer valuable opportunities to both investors and occupiers.

Healthcare providers across Canada will be able to capture adverse events in the Auxita platform through integration with MyMeds&Me’s pharmacovigilance SaaS platform, Reportum.